Immugenia

Logo Immugenia

Founded

2020

Incubated into ACET

2021

External links

Website

Immugenia Inc. is developing the next generation of CAR-T therapy to treat and prevent relapses in hematological and solid cancers. This is achieved by engineering the patients’ hematopoietic stem cells and leveraging their synergistic activity. This provides patients with a one-and-done treatment to fight hard-to-treat cancers and prevent relapses.